Last reviewed 2026-05-20 · How we verify

Coliopan (BUTROPIUM)

Phase 2 active Small molecule ✓ Verified May 2026

Coliopan (generic name: BUTROPIUM) is a butropium drug. It is currently in Phase 2 development for Gastritis.

Coliopan works by blocking muscarinic acetylcholine receptors in the stomach, reducing acid production and inflammation.

Coliopan is a small molecule medication with the chemical name butropium bromide. It is also known by other names, including butropium bromide, bromure de butropium, bromuro de butropio, and butropium bromide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUTROPIUM
Drug class	butropium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your stomach has a 'brake' and an 'accelerator' system. The brake system helps to slow down acid production, while the accelerator system speeds it up. Coliopan works by pressing the brake pedal, reducing acid production and helping to soothe the stomach lining.

Approved indications

Gastritis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Coliopan CI brief — competitive landscape report
Coliopan updates RSS · CI watch RSS

Frequently asked questions about Coliopan

What is Coliopan?

Coliopan (BUTROPIUM) is a butropium drug, indicated for Gastritis.

How does Coliopan work?

Coliopan works by blocking muscarinic acetylcholine receptors in the stomach, reducing acid production and inflammation.

What is Coliopan used for?

Coliopan is indicated for Gastritis.

What is the generic name of Coliopan?

BUTROPIUM is the generic (nonproprietary) name of Coliopan.

What drug class is Coliopan in?

Coliopan belongs to the butropium class. See all butropium drugs at /class/butropium.

What development phase is Coliopan in?

Coliopan is in Phase 2.

Drug class: All butropium drugs
Therapeutic area: All drugs in Other
Indication: Drugs for Gastritis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing